Swiss Group for Clinical Cancer Research: all 106 studies

Page 1 of 2. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Adjuvant Aspirin Treatment for Colon Cancer PatientsTerminatedNCT02467582Phase 3Results posted
• Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPCTerminatedNCT04629781Phase 1
• SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph IICompletedNCT04480372Phase 2
• Prostate Cancer BiobankActive, not recruitingNCT04024475
• Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate CancerTerminatedNCT03921996Phase 3
• Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.TerminatedNCT03886649Phase 1
• Activity Program During Aromatase Inhibitor TherapyCompletedNCT03786198Not applicable
• Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)TerminatedNCT03762122Phase 2
• NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue SarcomaTerminatedNCT03524898Phase 1/2
• Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple MyelomaTerminatedNCT03520985Phase 2
• TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid TumorsTerminatedNCT03387917Phase 1
• Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell CarcinomaCompletedNCT03297593Phase 2
• Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.CompletedNCT03213301Phase 2
• Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.CompletedNCT02964689Phase 1
• SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After ProstatectomyTerminatedNCT02945813Phase 2
• ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.TerminatedNCT02933801Phase 2
• Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal CancerTerminatedNCT02910843Phase 1
• Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma PatientsCompletedNCT02877550Phase 1
• Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast CancerTerminatedNCT02833766Phase 2
• Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide AloneTerminatedNCT02640534Phase 2
• Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line ChemotherapyTerminatedNCT02597075Not applicable
• Rituximab With or Without Ibrutinib for Patients With Advanced Follicular LymphomaTerminatedNCT02451111Phase 2
• Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast CancerTerminatedNCT02404506Phase 2
• VPM1002BC in Recurrent Non-muscle Invasive Bladder CancerCompletedNCT02371447Phase 1/2
• Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell LymphomaTerminatedNCT02356458Phase 1/2
• Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutationCompletedNCT02311569Phase 2
• Impact of a Surgical Sealing Patch on Lymphatic Drainage After ALND for Breast CancerCompletedNCT02311543Phase 3
• Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive MyelomaCompletedNCT02188537Phase 2
• CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast CancerTerminatedNCT02067741Phase 2
• Early Hippocampal Avoidance Prophylactic Cranial Irradiation in Patients With LD SCLCCompletedNCT02058056Not applicable
• Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal AgentsWithdrawnNCT02053311Phase 3
• LDE225 and Paclitaxel in Solid TumorsCompletedNCT01954355Phase 1
• Adjuvant Treatment Recommendation and Oncotype DX® in Early Breast CancerCompletedNCT01926964
• Trastuzumab & Pertuzumab Followed by T-DM1 in MBCCompletedNCT01835236Phase 2
• Cetuximab for Elderly Patients With mCRCTerminatedNCT01718808Phase 2
• Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel TherapyCompletedNCT01707966Phase 3
• Therapy De-escalation in Seminoma Stage IIA/BTerminatedNCT01593241Phase 2
• Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple MyelomaTerminatedNCT01555281Phase 1/2
• Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular LymphomaTerminatedNCT01307605Phase 2
• Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After SurgeryCompletedNCT01272050Phase 3
• Metformin Hydrochloride as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Prostate CancerCompletedNCT01243385Phase 2
• Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic CancerCompletedNCT01164709Phase 1
• Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor TherapyCompletedNCT01160718Phase 2
• Metronomic Therapy in Metastatic Breast Cancer.CompletedNCT01131195Phase 3
• Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).CompletedNCT01116219Phase 2
• Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by SurgeryCompletedNCT01107639Phase 3
• Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01059188Phase 2
• Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT01057342Phase 2
• Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver CancerTerminatedNCT01009801Phase 1/2
• Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver CancerCompletedNCT01005199Phase 2
• F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast CancerCompletedNCT00992706Phase 3
• Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell LymphomaCompletedNCT00987493Phase 1/2
• Everolimus as First-Line Therapy in Treating Patients With Prostate CancerCompletedNCT00976755Phase 2
• External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal CancerCompletedNCT00869570Phase 1/2
• Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal CancerCompletedNCT00814619Phase 2
• Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by SurgeryCompletedNCT00777894Phase 1/2
• Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive ChemotherapyCompletedNCT00739388Phase 2
• Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate CancerCompletedNCT00728663Phase 2
• Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal TumorsCompletedNCT00568750Phase 2
• Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By SurgeryCompletedNCT00568048Phase 2
• Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal CancerTerminatedNCT00544700Phase 3
• PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and PrednisoneCompletedNCT00544219Not applicable
• Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT00516412Phase 2
• Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by SurgeryCompletedNCT00514228Phase 2
• E-MOSAIC Electronic Tool to Monitor SymptomsCompletedNCT00477919
• Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by SurgeryCompletedNCT00445861Phase 1/2
• Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast CancerCompletedNCT00445406Phase 2
• Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous TreatmentCompletedNCT00392691Phase 1
• Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLCCompletedNCT00354549Phase 2
• Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural MesotheliomaCompletedNCT00334594Phase 2
• Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By SurgeryCompletedNCT00238407Phase 2
• Rectal Reconstruction in Treating Patients Who Are Undergoing Surgery for Rectal CancerCompletedNCT00238381Phase 3
• Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast CancerCompletedNCT00238290Phase 2
• Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell LymphomaCompletedNCT00234026Phase 2
• Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By SurgeryCompletedNCT00227734Phase 2
• Rituximab in Treating Patients With Follicular Non-Hodgkin's LymphomaCompletedNCT00227695Phase 3
• Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By SurgeryCompletedNCT00217711Phase 1/2
• Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerCompletedNCT00217698Phase 2
• Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract CancerCompletedNCT00073905Phase 2
• Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLLCompletedNCT00072007Phase 2
• Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate CancerCompletedNCT00031889Phase 2
• Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast CancerCompletedNCT00031876Phase 1/2
• Combination Chemotherapy Followed by Radiation Therapy Before Surgery in Treating Patients With Stage IIIB NSCLCCompletedNCT00030810Phase 2
• Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal CancerCompletedNCT00030797Phase 2
• Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC PatientsCompletedNCT00030771Phase 3
• Combination Chemotherapy Before Surgery in Treating Patients With Mesothelioma of the LungCompletedNCT00030745Phase 2
• Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic CancerCompletedNCT00030732Phase 3
• Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00006023Phase 2
• Combination Chemotherapy and Surgery in Treating Patients With Locally Advanced Stomach CancerCompletedNCT00005060Phase 3
• Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2TerminatedNCT00004935Phase 3
• Combination Chemotherapy in Treating Patients With Advanced Stomach CancerCompletedNCT00004873Phase 2
• Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic SyndromeCompletedNCT00004208Phase 3
• Capecitabine and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal CancerCompletedNCT00004187Phase 1/2
• Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone InvolvementCompletedNCT00003902Phase 1/2
• Biological Therapy in Treating Patients With Bladder CancerCompletedNCT00003779Phase 3
• Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine TherapyCompletedNCT00003757Phase 2
• Daily or Weekly Cladribine in Treating Patients With Hairy Cell LeukemiaCompletedNCT00003746Phase 3
• Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell LymphomaCompletedNCT00003280Phase 3
• Vinorelbine in Treating Patients With Metastatic Prostate CancerCompletedNCT00003259Phase 2
• Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung CancerCompletedNCT00003231Phase 2

← Swiss Group for Clinical Cancer Research overview and focus areas